If this email is not displayed correctly please click here

Healthcare & Life Sciences

27 February 2019
Brandon Heard Apotex seeks leave to appeal ramipril pleadings amendment decision

Canada - Smart & Biggar/Fetherstonhaugh

The Ontario Court of Appeal granted Sanofi and Schering leave to amend their defences to plead the Supreme Court of Canada's decision in AstraZeneca Canada Inc v Apotex Inc. In the underlying action, Apotex relied on the invalidity decision in Sanofi-Aventis Canada v Apotex Inc as a central element of its novel claims under the Ontario Statute of Monopolies, the UK Statute of Monopolies and the Trademarks Act. Apotex recently applied for leave to appeal to the Supreme Court of Canada.

Author: Brandon Heard
Read more
Jonas Löfgren Trilogue negotiations: originator company compensation for parallel imported products

Sweden - Westerberg & Partners Advokatbyrå Ab

The Stockholm Administrative Court recently ruled that under the so-called 'trilogue negotiations' between pharmaceutical companies, the Dental and Pharmaceutical Benefits Agency and the Swedish regions could require an originator company to compensate them for products marketed by parallel importers.

Authors: Jonas Löfgren, Måns Ullman
Read more

Recent updates

Scott D Stein DOJ announces more than $2.5 billion in FY 2018 False Claims Act recoveries from healthcare industry

USA - Sidley Austin LLP

Authors: Scott D Stein, Neil G Nandi
Tierney GB Deluzio Health Canada requests feedback on company names added to Generic Submissions Under Review List

Canada - Smart & Biggar/Fetherstonhaugh

Author: Tierney GB Deluzio
Christian di Mauro New medical device regulations: what liability do notified bodies face?

Italy - Hogan Lovells

Authors: Christian di Mauro, Riccardo Fruscalzo
Kirian Claeyé Anti-tampering devices – fading boundaries of parallel trade?

Belgium - ALTIUS

Authors: Kirian Claeyé, Laura Traest